Singapore, May 28 -- Taxis Pharmaceuticals, a US-based clinical stage company at the forefront of developing therapies to treat multidrug-resistant bacterial infections and combat antimicrobial resistance (AMR), has received a $2.9 million grant, to be awarded over three years, from the National Institute of Allergy and Infectious Disease (NIAID), one of the institutes of the National Institutes of Health (NIH).

The grant will allow Taxis to further advance R&D efforts for its dihydrofolate reductase inhibitors (DHFRIs) as a novel approach to combat multi-drug resistant gonorrhea (MDRSG, commonly referred to as Super Gonorrhea), a rapidly spreading deadly and highly resistant strain ofNeisseria gonorrhoeae.

DHFRIs target and inhibit the...